Symbols / ASMB
ASMB Chart
About
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 468.82M |
| Enterprise Value | 243.92M | Income | -38.55M | Sales | 37.19M |
| Book/sh | 11.55 | Cash/sh | 14.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 73 | IPO | — |
| P/E | — | Forward P/E | -8.46 | PEG | — |
| P/S | 12.61 | P/B | 2.57 | P/C | — |
| EV/EBITDA | -5.63 | EV/Sales | 6.56 | Quick Ratio | 4.39 |
| Current Ratio | 4.44 | Debt/Eq | 1.51 | LT Debt/Eq | — |
| EPS (ttm) | -4.55 | EPS next Y | -3.50 | EPS Growth | — |
| Revenue Growth | 57.60% | Earnings | 2025-11-10 16:00 | ROA | -15.96% |
| ROE | -36.94% | ROIC | — | Gross Margin | -66.29% |
| Oper. Margin | -100.87% | Profit Margin | -103.65% | Shs Outstand | 15.82M |
| Shs Float | 7.46M | Short Float | 11.39% | Short Ratio | 14.16 |
| Short Interest | — | 52W High | 39.71 | 52W Low | 7.75 |
| Beta | 1.15 | Avg Volume | 118.48K | Volume | 94.34K |
| Target Price | $47.75 | Recom | None | Prev Close | $29.95 |
| Price | $29.64 | Change | -1.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$47.75
Mean price target
2. Current target
$29.64
Latest analyst target
3. DCF / Fair value
$-13.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$29.64
Low
$39.00
High
$62.00
Mean
$47.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-11-20 | main | Mizuho | Outperform → Outperform | $40 |
| 2025-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-24 | init | JMP Securities | — → Market Outperform | $38 |
| 2025-09-08 | main | Guggenheim | Buy → Buy | $39 |
| 2025-03-25 | init | Guggenheim | — → Buy | $31 |
| 2025-03-24 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-27 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-06-20 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-01 | reit | HC Wainwright & Co. | — → Neutral | — |
- Assembly Biosciences, Inc. (NASDAQ:ASMB) stock most popular amongst individual investors who own 48%, while public companies hold 29% - Yahoo Finance Fri, 20 Jun 2025 07
- Trading the Move, Not the Narrative: (ASMB) Edition - Stock Traders Daily Wed, 18 Feb 2026 01
- Assembly Biosciences Gains 13%, Insider Trades Reap Benefit - simplywall.st ue, 14 Oct 2025 07
- Jefferies raises Assembly Biosciences stock price target to $62 on HSV data - Investing.com Wed, 10 Dec 2025 08
- Drugmakers move closer to first new genital herpes treatment in 25 years - Stock Titan Mon, 22 Dec 2025 08
- Assembly Biosciences (ASMB) Price Target Increased by 24.84% to 48.70 - Nasdaq Sun, 21 Dec 2025 08
- Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies - Slideshow (NASDAQ:ASMB) 2025-12-08 - Seeking Alpha Mon, 08 Dec 2025 08
- Here's Why We're Not At All Concerned With Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Situation - Yahoo Finance hu, 13 Nov 2025 08
- Assembly Biosciences Presents Phase 1a Clinical Data for Novel HSV Inhibitors ABI-5366 and ABI-1179 at World Congress and Herpesvirus Workshop | ASMB Stock News - Quiver Quantitative Sat, 26 Jul 2025 07
- Will ASMB stock outperform international peers - Trade Performance Summary & Proven Capital Preservation Tips - mfd.ru Wed, 18 Feb 2026 17
- Companies Like Assembly Biosciences (NASDAQ:ASMB) Can Afford To Invest In Growth - simplywall.st ue, 02 Dec 2025 08
- Assembly Biosciences stock rises after promising HSV drug results - Investing.com Mon, 08 Dec 2025 08
- Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? - Yahoo Finance Mon, 22 Sep 2025 07
- Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27% - simplywall.st hu, 22 Jan 2026 08
- With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Yahoo Finance Wed, 24 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2295920 | 55033202 | — | Purchase at price 23.97 per share. | GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-08 00:00:00 | D |
| 1 | 300 | — | — | Stock Award(Grant) at price 0.00 per share. | BJORKQUIST JEANETTE M | Officer | — | 2025-06-16 00:00:00 | D |
| 2 | 197 | 1940 | — | Sale at price 9.85 per share. | WHITE NICOLE S | Officer | — | 2025-03-31 00:00:00 | D |
| 3 | 355 | 3496 | — | Sale at price 9.85 per share. | OKAZAKI JASON A | Chief Executive Officer | — | 2025-03-31 00:00:00 | D |
| 4 | 180 | 1773 | — | Sale at price 9.85 per share. | BJORKQUIST JEANETTE M | Officer | — | 2025-03-31 00:00:00 | D |
| 5 | 1655 | — | — | Stock Award(Grant) at price 0.00 per share. | BJORKQUIST JEANETTE M | Officer | — | 2025-03-28 00:00:00 | D |
| 6 | 3202 | 49998 | — | Purchase at price 15.61 per share. | HOUGHTON MICHAEL | Director | — | 2024-12-30 00:00:00 | I |
| 7 | 940499 | 14869289 | — | Purchase at price 15.81 per share. | GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-19 00:00:00 | D |
| 8 | 25000 | 371994 | — | Purchase at price 14.85 - 15.00 per share. | SCHORNSTEIN ALEXANDER | Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-25 00:00:00 | D |
| 9 | 40 | 652 | — | Sale at price 16.29 per share. | WHITE NICOLE S | Officer | — | 2024-11-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -791.12K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.02 |
| NormalizedEBITDA | -45.29M | -64.20M | -93.62M | -48.95M |
| TotalUnusualItems | 0.00 | -41.64M | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -41.64M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -40.18M | -61.23M | -93.09M | -129.85M |
| ReconciledDepreciation | 129.00K | 450.00K | 498.00K | 466.00K |
| EBITDA | -45.29M | -64.20M | -93.62M | -90.58M |
| EBIT | -45.42M | -64.65M | -94.11M | -91.05M |
| NetInterestIncome | 5.57M | 3.45M | 1.02M | 302.00K |
| InterestIncome | 5.57M | 3.45M | 1.02M | 302.00K |
| NormalizedIncome | -40.18M | -61.23M | -93.09M | -89.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -40.18M | -61.23M | -93.09M | -129.85M |
| TotalExpenses | 73.94M | 71.81M | 94.11M | 97.30M |
| TotalOperatingIncomeAsReported | -45.42M | -64.65M | -94.11M | -132.69M |
| DilutedAverageShares | 6.00M | 4.58M | 4.03M | 3.61M |
| BasicAverageShares | 6.00M | 4.58M | 4.03M | 3.61M |
| DilutedEPS | -6.69 | -13.38 | -23.04 | -36.00 |
| BasicEPS | -6.69 | -13.38 | -23.04 | -36.00 |
| DilutedNIAvailtoComStockholders | -40.18M | -61.23M | -93.09M | -129.85M |
| NetIncomeCommonStockholders | -40.18M | -61.23M | -93.09M | -129.85M |
| NetIncome | -40.18M | -61.23M | -93.09M | -129.85M |
| NetIncomeIncludingNoncontrollingInterests | -40.18M | -61.23M | -93.09M | -129.85M |
| NetIncomeContinuousOperations | -40.18M | -61.23M | -93.09M | -129.85M |
| TaxProvision | 330.00K | 33.00K | 0.00 | -2.53M |
| PretaxIncome | -39.85M | -61.20M | -93.09M | -132.39M |
| OtherIncomeExpense | -41.64M | |||
| SpecialIncomeCharges | 0.00 | -41.64M | ||
| ImpairmentOfCapitalAssets | 0.00 | 41.64M | ||
| NetNonOperatingInterestIncomeExpense | 5.57M | 3.45M | 1.02M | 302.00K |
| InterestIncomeNonOperating | 5.57M | 3.45M | 1.02M | 302.00K |
| OperatingIncome | -45.42M | -64.65M | -94.11M | -91.05M |
| OperatingExpense | 73.94M | 71.81M | 94.11M | 97.30M |
| ResearchAndDevelopment | 55.93M | 48.90M | 69.98M | 68.52M |
| SellingGeneralAndAdministration | 18.01M | 22.91M | 24.13M | 28.78M |
| GeneralAndAdministrativeExpense | 18.01M | 22.91M | 24.13M | 28.78M |
| OtherGandA | 18.01M | 22.91M | 24.13M | 28.78M |
| TotalRevenue | 28.52M | 7.16M | 0.00 | 6.25M |
| OperatingRevenue | 28.52M | 7.16M | 0.00 | 6.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 7.46M | 5.48M | 4.07M | 4.01M |
| ShareIssued | 7.46M | 5.48M | 4.07M | 4.01M |
| TotalDebt | 3.09M | 2.34M | 3.46M | 6.48M |
| TangibleBookValue | 33.36M | 41.10M | 82.66M | 168.93M |
| InvestedCapital | 33.36M | 41.10M | 82.66M | 168.93M |
| WorkingCapital | 67.70M | 94.56M | 80.67M | 138.13M |
| NetTangibleAssets | 33.36M | 41.10M | 82.66M | 168.93M |
| CapitalLeaseObligations | 3.09M | 2.34M | 3.46M | 6.48M |
| CommonStockEquity | 33.36M | 41.10M | 82.66M | 168.93M |
| TotalCapitalization | 33.36M | 41.10M | 82.66M | 168.93M |
| TotalEquityGrossMinorityInterest | 33.36M | 41.10M | 82.66M | 168.93M |
| StockholdersEquity | 33.36M | 41.10M | 82.66M | 168.93M |
| GainsLossesNotAffectingRetainedEarnings | -211.00K | -81.00K | -803.00K | -419.00K |
| OtherEquityAdjustments | -211.00K | -81.00K | -803.00K | -419.00K |
| RetainedEarnings | -825.92M | -785.75M | -724.52M | -631.43M |
| AdditionalPaidInCapital | 859.49M | 826.92M | 807.98M | 800.73M |
| CapitalStock | 7.00K | 5.00K | 4.00K | 48.00K |
| CommonStock | 7.00K | 5.00K | 4.00K | 48.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 85.81M | 95.73M | 19.13M | 22.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 38.01M | 56.50M | 2.83M | 6.06M |
| NonCurrentDeferredLiabilities | 35.38M | 55.38M | 2.73M | 2.73M |
| NonCurrentDeferredRevenue | 35.38M | 55.38M | 2.73M | 2.73M |
| LongTermDebtAndCapitalLeaseObligation | 2.63M | 1.12M | 101.00K | 3.33M |
| LongTermCapitalLeaseObligation | 2.63M | 1.12M | 101.00K | 3.33M |
| CurrentLiabilities | 47.80M | 39.23M | 16.30M | 16.07M |
| CurrentDeferredLiabilities | 37.62M | 30.91M | 0.00 | |
| CurrentDeferredRevenue | 37.62M | 30.91M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 461.00K | 1.22M | 3.36M | 3.15M |
| CurrentCapitalLeaseObligation | 461.00K | 1.22M | 3.36M | 3.15M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.48M | 5.48M | 6.23M | 6.43M |
| PayablesAndAccruedExpenses | 3.24M | 1.61M | 6.70M | 6.50M |
| CurrentAccruedExpenses | 2.66M | 1.15M | 4.21M | 3.84M |
| Payables | 585.00K | 461.00K | 2.49M | 2.66M |
| AccountsPayable | 585.00K | 461.00K | 2.49M | 2.66M |
| TotalAssets | 119.17M | 136.82M | 101.79M | 191.06M |
| TotalNonCurrentAssets | 3.67M | 3.04M | 4.83M | 36.86M |
| OtherNonCurrentAssets | 312.00K | 312.00K | 889.00K | 1.70M |
| InvestmentsAndAdvances | 0.00 | 27.97M | ||
| OtherInvestments | 0.00 | 27.97M | ||
| InvestmentinFinancialAssets | 27.97M | |||
| AvailableForSaleSecurities | 27.97M | |||
| NetPPE | 3.35M | 2.72M | 3.94M | 7.18M |
| AccumulatedDepreciation | -210.00K | -1.69M | -1.21M | |
| GrossPPE | 3.35M | 2.72M | 5.62M | 8.39M |
| Leases | 62.00K | 1.63M | 1.63M | |
| OtherProperties | 3.35M | 2.72M | 3.30M | 6.06M |
| MachineryFurnitureEquipment | 238.00K | 699.00K | 699.00K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 115.50M | 133.79M | 96.97M | 154.20M |
| OtherCurrentAssets | 3.42M | 3.50M | 4.41M | 7.24M |
| PrepaidAssets | 7.24M | |||
| Receivables | 0.00 | 43.00K | 944.00K | 336.00K |
| AccountsReceivable | 0.00 | 43.00K | 944.00K | 336.00K |
| CashCashEquivalentsAndShortTermInvestments | 112.08M | 130.25M | 91.61M | 146.63M |
| OtherShortTermInvestments | 73.73M | 110.41M | 39.19M | 101.00M |
| CashAndCashEquivalents | 38.34M | 19.84M | 52.42M | 45.63M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -51.15M | 22.49M | -84.56M | -96.49M |
| IssuanceOfCapitalStock | 29.29M | 13.69M | 325.00K | 52.81M |
| CapitalExpenditure | -28.00K | -255.00K | -102.00K | -3.10M |
| IncomeTaxPaidSupplementalData | 421.00K | 0.00 | ||
| EndCashPosition | 38.34M | 19.84M | 52.42M | 45.63M |
| BeginningCashPosition | 19.84M | 52.42M | 45.63M | 59.44M |
| ChangesInCash | 18.50M | -32.58M | 6.79M | -13.82M |
| FinancingCashFlow | 29.45M | 13.82M | 614.00K | 53.06M |
| CashFlowFromContinuingFinancingActivities | 29.45M | 13.82M | 614.00K | 53.06M |
| ProceedsFromStockOptionExercised | 155.00K | 129.00K | 289.00K | 258.00K |
| NetCommonStockIssuance | 29.29M | 13.69M | 325.00K | 52.81M |
| CommonStockIssuance | 29.29M | 13.69M | 325.00K | 52.81M |
| InvestingCashFlow | 40.17M | -69.14M | 90.64M | 26.52M |
| CashFlowFromContinuingInvestingActivities | 40.17M | -69.14M | 90.64M | 26.52M |
| NetInvestmentPurchaseAndSale | 40.20M | -68.91M | 89.24M | 27.25M |
| SaleOfInvestment | 130.70M | 65.02M | 116.83M | 187.70M |
| PurchaseOfInvestment | -90.50M | -133.92M | -27.58M | -160.45M |
| NetBusinessPurchaseAndSale | 0.00 | 1.50M | 1.50M | |
| SaleOfBusiness | 0.00 | 1.50M | 1.50M | |
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | -28.00K | -231.00K | -102.00K | -2.24M |
| SaleOfPPE | 0.00 | 24.00K | 0.00 | 857.00K |
| PurchaseOfPPE | -28.00K | -255.00K | -102.00K | -3.10M |
| OperatingCashFlow | -51.12M | 22.74M | -84.46M | -93.40M |
| CashFlowFromContinuingOperatingActivities | -51.12M | 22.74M | -84.46M | -93.40M |
| ChangeInWorkingCapital | -11.95M | 76.34M | -2.12M | -11.40M |
| ChangeInOtherWorkingCapital | -13.29M | 83.56M | -6.25M | |
| ChangeInOtherCurrentLiabilities | -1.40M | -3.77M | -3.67M | -3.79M |
| ChangeInOtherCurrentAssets | 0.00 | 577.00K | 814.00K | 4.69M |
| ChangeInPayablesAndAccruedExpense | 2.63M | -5.84M | 14.00K | -8.05M |
| ChangeInAccruedExpense | 2.51M | -3.81M | 180.00K | -6.11M |
| ChangeInPayable | 124.00K | -2.03M | -166.00K | -1.94M |
| ChangeInAccountPayable | 124.00K | -2.03M | -166.00K | -1.94M |
| ChangeInPrepaidAssets | 73.00K | 916.00K | 1.33M | 1.11M |
| ChangeInReceivables | 43.00K | 901.00K | -608.00K | 894.00K |
| ChangesInAccountReceivables | 43.00K | 901.00K | -608.00K | 894.00K |
| OtherNonCashItems | 1.42M | 3.51M | 3.50M | 3.84M |
| StockBasedCompensation | 3.12M | 5.12M | 6.59M | 5.24M |
| AssetImpairmentCharge | 0.00 | 41.64M | ||
| AmortizationOfSecurities | -3.66M | -1.58M | 155.00K | 586.00K |
| DeferredTax | 0.00 | -2.53M | ||
| DeferredIncomeTax | 0.00 | -2.53M | ||
| DepreciationAmortizationDepletion | 129.00K | 450.00K | 498.00K | 466.00K |
| DepreciationAndAmortization | 129.00K | 450.00K | 498.00K | 466.00K |
| OperatingGainsLosses | 139.00K | -1.38M | ||
| GainLossOnSaleOfPPE | 0.00 | 139.00K | 0.00 | 1.62M |
| NetIncomeFromContinuingOperations | -40.18M | -61.23M | -93.09M | -129.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ASMB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|